PubMed Health⌕ Search

Biomedical subjects

A Ceci

Publications and source records attributed to A Ceci.

77 records · Page 5Linked to original sources
PubMedDate not supplied

[Massive therapy and transplant of autologous bone marrow in childhood lymphomas and solid tumors. State of the art and perspectives].

The role of massive therapy followed by autologous bone marrow transplantation (ABMT) in pediatric tumours is reviewed. The rationale of such an approach based on dose-response relationship in clinical oncology, the usefulness of total body irradiation (TBI) as a part of conditioning regimens, and phase I and II trials with high dose drug combinations are discussed. The results of ABMT in lymphomas, sarcomas, neuroblastomas and other tumours are critically analyzed with special emphasis on prognostic factors, differences among conditioning regimens, intensive therapy morbidity and marrow purging procedures. Finally future perspectives and questions still unsolved are briefly summarized.

Antineoplastic Agents↗
PubMedDate not supplied

[Prognostic factors in non-Hodgkin's lymphoma in childhood].

38 children with Non-Hodgkin Lymphoma (age 15 months - 17 years; 27 males and 11 females) have been treated between 1974 and 1982. They have been divided in two different groups: a Good Prognosis group for patients with complete resectable disease and a Poor Prognosis group including patients with mediastinal, bone marrow or CNS involvement or with diffuse and non completely resectable localization. In the Good Prognosis group there were 100% Complete Remission, 12.5% Local Relapses and 12.5% deaths. 88% of patients are alive at 8 1/2 years follow-up. In the Poor Prognosis group there were 83% Complete Remission, 50% Relapses (8 in the first year, 2 in the second and 5 in the third and no more in the next years) and 60% Deaths; 30% of patients are off-therapy with a survival of 40% at 8 1/2 years follow-up. Among the 19 patients with mediastinal involvement there were 84.2% Complete Remission, 68.4% Relapses, 63.1% Deaths and 26.6% off therapy patients. Among the 19 patients with mediastinal involvement there were 84.2% Complete Remission, 68.4% Relapses, 63.1% Deaths and 26.6% off therapy patients. Survival is 70% for the group without mediastinal involvement and 35% for the group with mediastinal involvement. Burkitt-type Lymphoma has a survival of 30% in contrast to the 60% survival for all the others histological types. In summary we conclude that the distinction between Good Prognosis and Poor Prognosis groups, on the basis of a clinical stage involvement and Burkitt histology have an important role for prognosis of Non-Hodgkin Lymphoma in children.

Adolescent↗
PubMedDate not supplied

[Histiocytosis X: historical review and therapeutic prospectives].

A number of factors should influence the choice of therapy in H.X. The three most important are: etiology, natural history and prognostic factors. At this time, we can identify 2 groups of patients: - the first is characterized by age greater than 2 years, bone involvement, absence of organ dysfunction, long survival, low mortality and high frequency of late effects (Good Risk Group); - the second group by age less than 2 years, soft tissue (+/- bone) involvement, presence of organ dysfunction and high mortality (Poor Risk Group). Chemotherapy appears to improve survival and Complete Remission rate in the Poor Risk Group but not in the Good Risk Group. New advances, i.e. immunotherapy, are in progress to reduce mortality in Poor Risk patients, late effects in Good Risk patients and related therapy sequelae.

Antineoplastic Combined Chemotherapy Protocols↗